🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

RecruitingNAAges any - anyAllMiltenyi Biomedicine GmbH
NCT06508775 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up. * Patient has provided informed consent prior to enrollment. Exclusion Criteria: * No exclusion criteria
💊

What it tests

  • MB-CART19.1
  • MB-CART20.1
  • MB-CART2019.1
📍

Where

7 sites
Charité Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Köln
Cologne, Germany
Uniklinikum Erlangen
Erlangen, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Universitätsklinikum Münster
Münster, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Universitäts-Kinderklinik Würzburg
Würzburg, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy